Management of Hyperinsulinemia in Patients with Chronic Kidney Disease

Glycemic Monitoring and Targets

The American College of Physicians recommends HbA1c as the primary tool for monitoring glycemic control in CKD stage 3b, with an individualized target ranging from <6.5% to <8.0% based on hypoglycemia risk and comorbidities 1, 2, 3
Continuous glucose monitoring (CGM) may be useful in patients with discordance between HbA1c and clinical symptoms, as it is not affected by kidney function 1, 4

The National Kidney Foundation recommends metformin as first-line therapy for patients with CKD stage 3b, with a reduced dose when eGFR is <45 ml/min/1.73m² 5, 6, 7
SGLT2 inhibitors are recommended as first-line therapy alongside metformin for patients with eGFR ≥30 ml/min/1.73m², providing cardiorenal protection independent of their glucose-lowering effects 6, 7
GLP-1 receptor agonists are preferred over other agents due to their cardiovascular benefits and low hypoglycemia risk, and should be added if glycemic targets are not achieved with metformin and SGLT2i 5, 6, 7
First-generation sulfonylureas should be avoided in CKD stage 3b due to increased risk of hypoglycemia, and glipizide or gliclazide should be preferred if a sulfonylurea is needed 8

The Academy of Nutrition and Dietetics recommends a balanced diet high in vegetables, fruits, whole grains, fiber, legumes, plant-based proteins, unsaturated fats, and nuts, with limited sodium intake (<2 g/day) and reduced consumption of processed meats, refined carbohydrates, and sweetened beverages 4, 7, 9
The American Heart Association recommends moderate-intensity physical activity for at least 150 minutes per week, adjusted to cardiovascular and physical tolerance, and advises against sedentary behavior 4, 5, 7
Weight loss is encouraged for patients with obesity, as it may improve both insulin sensitivity and kidney function 5, 7

The National Kidney Foundation recommends monitoring eGFR more frequently when <60 ml/min/1.73m², and assessing for medication side effects, particularly hypoglycemia with insulin-sensitizing agents 5, 8
The American College of Cardiology recommends screening for cardiovascular complications, as patients with CKD, prediabetes, and hyperinsulinemia have increased cardiovascular risk 6